Japan Quasi-Drug Approval for Cosmetics: Regulatory Pathway for Taiwan Beauty Brands

Japan's pharmaceutical and cosmetics regulatory system, governed by the Pharmaceutical and Medical Device Act (PMD Act, formerly known as the Pharmaceutical Affairs Law or Yakujiho), creates a unique product category that does not exist in most other markets: quasi-drugs (iyaku-bugaihin). Quasi-drugs occupy a regulatory space between ordinary cosmetics (keshohin) and pharmaceuticals (iyakuhin), covering products that have mild pharmacological effects on the human body. Common quasi-drug cosmetics categories include medicated cosmetics for whitening (bihaku), anti-acne (nikibi-yobo), anti-dandruff shampoos, deodorants, hair growth promoters, and sunscreens with SPF claims above a certain threshold.

For Taiwan beauty brands, the quasi-drug pathway is strategically important because it allows marketing with specific efficacy claims that ordinary cosmetics cannot make. An ordinary cosmetic in Japan can only claim to "beautify" or "maintain healthy appearance" in general terms, while a quasi-drug can claim specific effects such as "prevents melanin production" or "kills acne-causing bacteria." These efficacy claims command premium pricing in the Japanese market, where consumers are highly brand-literate and actively seek products with medicated (iyaku) positioning. The Japanese whitening skincare market alone is valued at approximately JPY 280 billion (USD 1.9 billion) annually, and quasi-drug products dominate this segment.

The regulatory authority for quasi-drug approval is the Pharmaceuticals and Medical Devices Agency (PMDA), which reviews applications on behalf of the Ministry of Health, Labour and Welfare (MHLW). The review process is more rigorous than ordinary cosmetics notification (which requires only a notification to PMDA before marketing) but less demanding than full pharmaceutical approval. Quasi-drug approval requires efficacy and safety data, manufacturing quality documentation, and compliance with approved active ingredient lists and concentration limits. The review timeline is typically 6 to 12 months for standard quasi-drug applications and 3 to 6 months for products using well-established active ingredients with existing Japanese precedent.

Taiwan beauty brands with products containing active ingredients such as tranexamic acid, arbutin, niacinamide, glycyrrhizinic acid, or salicylic acid should evaluate the quasi-drug pathway if they intend to make efficacy claims in the Japanese market. Products sold as ordinary cosmetics in Taiwan, the US, or Europe may qualify for quasi-drug status in Japan if they contain approved active ingredients at specified concentrations. The investment in quasi-drug approval (typically JPY 3 million to JPY 8 million including testing and regulatory consulting) is justified by the ability to command 20 to 40 percent price premiums over ordinary cosmetics in the same category.

The first step in the quasi-drug approval process is confirming that your product's active ingredients are on Japan's approved list of quasi-drug ingredients. MHLW maintains a list of approved active ingredients for each quasi-drug category, along with approved concentration ranges. For whitening products, approved actives include tranexamic acid (up to 2 percent), arbutin (up to 7 percent), ascorbic acid derivatives (various limits by derivative), and kojic acid (up to 1 percent). For anti-acne products, approved actives include isopropylmethylphenol, triclosan (being phased out), and salicylic acid. Using an ingredient not on the approved list requires a new active ingredient application, which adds 12 to 24 months and JPY 10 million or more to the timeline.

Formulation for the Japanese quasi-drug market must comply with MHLW's Quasi-Drug Standards (Iyaku-bugaihin Kijun), which specify not only active ingredient limits but also restrictions on excipients, preservatives, colorants, and fragrances. Several preservatives and colorants permitted in Taiwan, the US, or EU cosmetics are restricted or prohibited in Japanese quasi-drugs. Request the current Quasi-Drug Standards document from your Japanese regulatory consultant and cross-reference every ingredient in your formulation before finalizing the Japanese market product specification. Reformulation to comply with Japanese requirements is common and should be budgeted into the product development timeline.

Pre-submission consultation with PMDA is strongly recommended for Taiwan brands without prior quasi-drug approval experience. PMDA offers pre-submission meetings (jizensodan) where applicants can discuss the proposed product, planned studies, and application strategy with PMDA reviewers. The pre-submission meeting fee is JPY 64,000 and the meeting is typically scheduled 30 to 60 days after request. The value of this meeting is substantial: PMDA reviewers will indicate whether your planned evidence package is likely to be sufficient, identify potential issues with your formulation, and clarify documentation requirements. Taiwan brands should bring their Japanese regulatory consultant and a technical representative to the pre-submission meeting.

You must designate a Marketing Authorization Holder (MAH) in Japan before submitting a quasi-drug application. The MAH must be a Japanese legal entity (kabushiki kaisha or godo kaisha) with a qualified Responsible Technical Officer (Sogo Sekininsha) who holds a pharmacist license or equivalent qualification. Taiwan companies cannot directly hold a quasi-drug marketing authorization without a Japanese corporate entity. The common approach is to partner with a Japanese cosmetics distributor or regulatory services firm that acts as the MAH. MAH fees range from JPY 500,000 to JPY 2 million per year per product, depending on the MAH's scope of services. Some MAH partners also handle importation, quality testing, adverse event reporting, and PMDA correspondence.

The quasi-drug application package submitted to PMDA includes: the Application Form (Shinsei-sho), product specification (Kikaku-sho), manufacturing and quality control documentation (Hinshitsu Kanri Shiryo), stability study reports, efficacy study reports, safety study reports, and label and package insert drafts. Each document must be in Japanese and follow PMDA's prescribed format. The application fee varies by product category but is typically JPY 145,000 to JPY 250,000 for a new quasi-drug approval. The fee is paid at the time of submission and is non-refundable regardless of the application outcome.

Efficacy studies for quasi-drugs must demonstrate that the product delivers the claimed effect under controlled conditions. For whitening products, the standard efficacy study measures the product's ability to inhibit melanin production using human skin patch tests or clinical studies with melanin measurement instruments. For anti-acne products, efficacy is measured through clinical studies with acne count reduction over 4 to 8 weeks. Efficacy studies must be conducted by qualified researchers at accredited testing laboratories, with Japanese PMDA-recognized facilities preferred. Common testing laboratories include Souken (Japan), CPTC Center (Japan), and Nichigan Hihuka (Japan). Study costs range from JPY 1.5 million to JPY 5 million depending on the category and study design.

Safety studies include a minimum battery of tests: human repeat insult patch test (HRIPT) for sensitization, human photo-patch test for photosensitivity (if the product is a leave-on product used on sun-exposed areas), ocular irritation test (if used near the eye area), and microbiological challenge testing for preservative efficacy. Products containing new excipients or excipients at concentrations exceeding existing Japanese precedent may require additional toxicological studies including acute oral toxicity, skin irritation, and mucosal irritation. Safety studies typically cost JPY 2 million to JPY 6 million and take 3 to 6 months to complete.

PMDA review of a complete quasi-drug application follows a standardized timeline. For products using well-established active ingredients with existing Japanese quasi-drug precedent, the target review period is 4 to 6 months. For products with less common active ingredients or novel excipients, the review period extends to 8 to 12 months. During review, PMDA may issue questions (shitsugi) requesting additional data or clarification. Questions must be answered within 60 days (extendable by request). The total number of question rounds is typically 1 to 3 for straightforward applications. After all questions are resolved and PMDA is satisfied, the approval is issued as a Quasi-Drug Approval Certificate (Iyaku-bugaihin Seizo Hanbai Shonin).

After receiving quasi-drug approval, several post-approval steps must be completed before market launch. Manufacturing site inspection by PMDA or a registered certification body is required to verify that the manufacturing facility complies with quasi-drug GMP standards (Quasi-Drug GMP, separate from pharmaceutical GMP). For Taiwan manufacturing facilities, PMDA may conduct an on-site audit (JPY 500,000 to JPY 1 million in fees plus travel costs) or accept an audit report from a PMDA-recognized third-party certification body. The GMP compliance certificate must be obtained before the first commercial batch can be manufactured for the Japanese market.

Product labeling for quasi-drugs must follow specific MHLW requirements that differ from ordinary cosmetics labeling. The label must include the product classification "iyaku-bugaihin" (quasi-drug), the approved active ingredients and their concentrations, the MAH name and address, the approved indications (written exactly as they appear on the approval certificate), usage directions, warnings, and batch number. The package insert (setsumei-sho) must include full ingredient disclosure and detailed safety information. Labels must be reviewed and approved by the MAH's Responsible Technical Officer before printing.

Adverse event reporting for quasi-drugs is mandatory. The MAH must report serious adverse events to PMDA within 15 days and other adverse events within 30 days. The MAH must also submit periodic safety update reports to PMDA at defined intervals. Taiwan brands should ensure their Japanese MAH partner has a functioning pharmacovigilance system before market launch. The cost of maintaining adverse event reporting typically runs JPY 300,000 to JPY 800,000 per year per product, often bundled into the MAH service agreement.

Market launch timing should be coordinated with the Japanese retail buying cycle. Japanese department stores and drugstore chains conduct new product intake during two primary seasons: spring (February to April) for summer and fall product launches, and autumn (August to October) for winter and spring product launches. Quasi-drug approvals that complete in May or June are ideally positioned for the autumn buying cycle, while approvals completing in November or December target the spring buying cycle. Taiwan brands should reverse-engineer their application timeline from the desired launch season, allowing 6 to 12 months for PMDA review, 3 to 6 months for testing, and 2 to 3 months for pre-application preparation.